drugset
drugset / Trial / NCT06151249

Evaluate the Meritup Oral Solution to Decrease Fatigue in Metastatic Breast Cancer Patients Receiving Chemotherapy

NCT06151249 ↗

Phase 2 Unknown 32 enrolled Chung Shan Medical University Phytofound Biotech Co., Ltd. · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

A randomized, double-blind, placebo-controlled, parallel study to evaluate the safety profile and ability of Meritup oral solution to decrease fatigue in metastatic breast cancer patients receiving chemotherapy.

Timeline

Start
2023-12-01
Primary completion
2025-11-30
Completion
2025-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Meritup Unknown 20 ml Oral

Indications

breast cancer